Search Results
10
Everything
Search Filters
Organization
Evaxion Biotech
Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting
March 25, 2025 16:30 ET
|
Evaxion Biotech
New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the American Association for Cancer Research (AACR) Annual Meeting These data will further add to the...
Evaxion to present at numerous upcoming conferences
March 04, 2025 08:00 ET
|
Evaxion Biotech
Evaxion will provide company and scientific updates at conferences in both the US and Europe during the coming weeks and months COPENHAGEN, Denmark, March 4, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX)...
Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package
February 25, 2025 08:00 ET
|
Evaxion Biotech
Originally planned as a two-year study, the trial has been extended by an additional year to collect three-year clinical outcome data The additional third year of EVX-01 dosing may provide further...
Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination
February 14, 2025 08:00 ET
|
Evaxion Biotech
Evaxion will remain listed on Nasdaq after successfully evidencing compliance with the Nasdaq minimum stockholders’ equity requirement Evaxion has restored its equity above the minimum requirement...
Evaxion announces closing of $10.8 million public offering
January 31, 2025 16:05 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, January 31, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the...
Evaxion announces pricing of $10.8 million public offering
January 30, 2025 08:00 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, January 30, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the...
Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement
January 28, 2025 08:15 ET
|
Evaxion Biotech
Following a constructive Nasdaq hearing panel on January 7, 2025, Evaxion has been granted a 180-day extension in relation to the Nasdaq minimum equity requirementEvaxion has currently restored its...
Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01
January 15, 2025 08:00 ET
|
Evaxion Biotech
Trial remains on track for completion and data readout in the second half of 2025 COPENHAGEN, Denmark, January 15, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio...
Evaxion announces completion of ADS ratio change
January 14, 2025 16:05 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, January 14, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines,...
Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change
January 10, 2025 08:00 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, January 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced...